Making the undruggable druggable
Unlocking challenging drug targets for the development of next-generation therapeutics
Selected Collaborations
It all starts with the drug target.
The majority of drug targets are so-called membrane proteins, and these are inherently unstable and challenging to investigate. Or so they were, until now.
Our proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies or small molecule drugs. Through our in-house and partnered pipelines, we drive the discovery of novel drugs.
Pushing drug development forward together
We work with top-tier pharma and biotech partners to unlock drug targets for drug development programs.
Pipeline
We are driving forward drug development in our partnered as well as internal pipelines.
News
Salipro Biotech at PEGS Boston, May 12-16!
2025-04-23
Salipro Biotech will be in PEGS Boston, taking place on May 12-16, ready to connect!
Our Business Development Director, Peter Jahnmatz, will present a poster highlighting the latest advancements on the Salipro® platform for the stabilization of challenging membrane protein targets for drug discovery applications.
If you are attending PEGS Boston, make sure to stop by Peter's poster to say hi and discover how the Salipro® technology can accelerate your pipeline programs targeting difficult membrane proteins such as GPCRs, ion channels and SLC transporters.
We look forward to connecting with fellow researchers and industry leaders at PEGS Boston!
For more information on PEGS Boston, please visit the website: https://www.pegsummit.com
Salipro Biotech speaker at Bio Korea 2025
2025-04-15
Salipro Biotech is heading to Bio Korea 2025, taking place from May 7-9 at COEX, Seoul, as part of the Swedish Life Science Delegation.
Don't miss Lorena's presentation at the Global BIO Connection (Country Day session) on Thursday, May 8 at 12:15. She will present Salipro Biotech and showcase the recent developments on the Salipro® technology to advance drug discovery against membrane protein drug targets.
You can also find us at the Swedish Pavilion booth, where our Business Development Manager, Lorena Galán-Acosta, will be available to explore potential collaborations opportunities.
Would you like to connect? Feel free to book a meeting via the Partnering Center : https://www.biokorea.org/program/partneringCenterParticipant.asp
We look forward to meeting you in Seoul!
More information on the conference here: https://www.biokorea.org/index.asp
New Publication! Salipro® Enables New Insights into Antibiotic Resistance
2025-04-11
Bacteria developing resistance to antibiotics is a major global health challenge. Understanding the mechanisms they use, like modifying their protective membranes, is crucial. A key player in this process for pathogens like Pseudomonas aeruginosa is the membrane protein MprF. But how does it work?
In this new study with the Salipro® platform published in Science Advances, Dr. Maike Bublitz-Meier and her team shed light on the structure and function of the Pseudomonas aeruginosa membrane protein MprF, a key player in antimicrobial resistance.
Key Highligths:
Salipro® enabled the first cryo-EM structure of MprF from P. aeruginosa (PaMprF).
The structure, combined with functional assays, revealed MprF acts as a versatile lipid scramblase, transporting lipids without external energy.
The findings provide a detailed blueprint for understanding a critical component of the bacterial defense system
This work suggests a novel mechanism for lipid transport involving membrane deformation and provides crucial insights into a potential target for combating antibiotic resistance.
Dive deeper into this study: M. T. K. Hankins, et al., MprF from Pseudomonas aeruginosa is a promiscuous lipid scramblase with broad substrate specificity. Sci. Adv.11,eads9135(2025).